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PEG-lipid micelles enable 
cholesterol efflux in Niemann-Pick 
Type C1 disease-based lysosomal 
storage disorder
Anna Brown1, Siddharth Patel1, Carl Ward2, Anna Lorenz1, Mauren Ortiz2, Allison DuRoss1, 
Fabian Wieghardt1, Amanda Esch3, Elsje G. Otten4, Laura M. Heiser3, Viktor I. Korolchuk4, 
Conroy Sun1,5, Sovan Sarkar2 & Gaurav Sahay1,3
2-Hydroxy-propyl-β-cyclodextrin (HPβCD), a cholesterol scavenger, is currently undergoing Phase 2b/3 
clinical trial for treatment of Niemann Pick Type C-1 (NPC1), a fatal neurodegenerative disorder that 
stems from abnormal cholesterol accumulation in the endo/lysosomes. Unfortunately, the extremely 
high doses of HPβCD required to prevent progressive neurodegeneration exacerbates ototoxicity, 
pulmonary toxicity and autophagy-based cellular defects. We present unexpected evidence that a 
poly (ethylene glycol) (PEG)-lipid conjugate enables cholesterol clearance from endo/lysosomes of 
Npc1 mutant (Npc1−/−) cells. Herein, we show that distearyl-phosphatidylethanolamine-PEG (DSPE-
PEG), which forms 12-nm micelles above the critical micelle concentration, accumulates heavily inside 
cholesterol-rich late endosomes in Npc1−/− cells. This potentially results in cholesterol solubilization 
and leakage from lysosomes. High-throughput screening revealed that DSPE-PEG, in combination 
with HPβCD, acts synergistically to efflux cholesterol without significantly aggravating autophagy 
defects. These well-known excipients can be used as admixtures to treat NPC1 disorder. Increasing PEG 
chain lengths from 350 Da-30 kDa in DSPE-PEG micelles, or increasing DSPE-PEG content in an array 
of liposomes packaged with HPβCD, improved cholesterol egress, while Pluronic block copolymers 
capable of micelle formation showed slight effects at high concentrations. We postulate that PEG-lipid 
based nanocarriers can serve as bioactive drug delivery systems for effective treatment of lysosomal 
storage disorders.
Niemann Pick Type C (NPC) is an inherited autosomal recessive lysosomal storage disorder that affects approx-
imately 1:120,000 children globally and results in hepatomegaly, progressive neurodegeneration, and finally 
death1,2. There are no current treatments available for children suffering from this devastating rare genetic disease. 
95% of NPC cases result from defects in the NPC1 protein, a large glycoprotein with 13-membrane-spanning 
domains that resides on the surface of late endosomes/lysosomes, with a sterol-sensing domain in the lumen 
that binds to cholesterol and enables egress to a cytoplasmic location3. NPC1 deficiency causes cholesterol accu-
mulation that manifests as enlargement of late endosomes/lysosomes, ultimately leading to neurodegeneration, 
especially loss of Purkinje fibers in the cerebellum, which leads to ataxia and cognitive loss4,5. HPβ CD is a Food 
and Drug Administration (FDA) approved hydrophilic small molecule excipient that has a hydrophobic pocket 
capable of binding and solubilizing cholesterol6. It is capable of the efflux and redistribution of cholesterol in 
mammalian cells7; however, it does not readily cross the blood brain barrier (only 0.2% reaches the brain on 
1Department of Pharmaceutical Sciences, College of Pharmacy, Collaborative Life Science Building, Oregon State 
University, Portland OR, USA. 2Institute of Cancer and Genomic Sciences, Institute of Biomedical Research, College 
of Medical and Dental Sciences, University of Birmingham, Edgbaston, Birmingham B15 2TT, United Kingdom. 
3Department of Biomedical Engineering, Collaborative Life Science Building, Oregon Health Science University, 
Portland OR, USA. 4Institute for Cell and Molecular Biosciences, Newcastle University Institute for Ageing, Campus 
for Ageing and Vitality, Newcastle University, Newcastle upon Tyne NE4 5PL, United Kingdom. 5Department of 
Radiation Medicine, School of Medicine, Oregon Health Science University, Portland OR, USA. Correspondence and 
requests for materials should be addressed to G.S. (email: sahay@ohsu.edu)
Received: 10 May 2016
Accepted: 25 July 2016
Published: 30 August 2016
OPEN
www.nature.com/scientificreports/
2Scientific RepoRts | 6:31750 | DOI: 10.1038/srep31750
systemic administration). In preclinical studies, a direct brain injection of HPβ CD into an NPC mouse model 
slowed the progression of neuronal loss and improved its survival8–11. Similar results were observed in a feline 
model of NPC disease, with an intra-cisternal administration used to decrease neurodegeneration and prolong 
survival12. More recently, an intrathecal cyclodextrin injection in a single NPC1 patient led to an increase in 
cholesterol redistribution in the central nervous system and improved vertical gaze palsy, a clinical indicator of 
NPC-linked neurodegeneration13. Based on these results, HPβ CD has entered NIH initiated Phase 2b/3 clinical 
trial, and the FDA has granted orphan drug status to further accelerate use of HPβ CD for treating NPC disease. 
An impediment to the clinical translation of HPβ CD is the exorbitant amount of drug required to clear choles-
terol in order to elicit a significant response. In a single example, a biweekly administered dose of 200 mg, with a 
total of 27 injections, applied by lumbar puncture to a child with NPC, slowed neurodegeneration but resulted in 
high-frequency hearing loss13. In the feline model, a subcutaneous injection of 8000 mg/kg was necessary to halt 
the loss of Purkinje neurons, but resulted in significant pulmonary toxicity12.
Liposomes are among the most advanced drug delivery systems for effective intracellular delivery, and thus 
an obvious carrier choice for delivery of HPβ CD to remove intracellular cholesterol aggregates14–16. Liposomal 
drug delivery vectors have several advantages, including prolonged circulation times, the potential to incorporate 
multiple drugs with different mechanisms of action and solubility, and surface decoration with a variety of tar-
geting ligands (e.g. transferrin) that can enable transport across the blood brain barrier14,17,18. Lipid nanoparticles 
(LNPs), a subset of liposomal vectors, have been very effective in the delivery of nucleic acids19,20. LNPs are shown 
to enter cells through endocytic portals and are selectively recycled through NPC1-positive late endosomes; the 
absence of NPC1 showed a 10–15-fold retention of LNPs inside cells which translated to improved nucleic acid 
delivery21. Hydrogenated soy phosphatidylcholine (HSPC) based liposomes that incorporate water-soluble small 
molecules in the core had a similar pattern of retention in the endo/lysosomal system of NPC1 deficient cells21. 
Based on these studies, we hypothesized that simple liposomal formulations would enhance site-specific deliv-
ery of HPβ CD into the cholesterol rich endo/lysosomes in Npc1 deficient mouse embryonic fibroblasts (MEFs). 
We created a small set of two-component liposomes from HSPC and distearyl-phosphatidylethanolamine con-
jugated with polyethylene glycol (DSPE-PEG), a common PEG-lipid known to improve nanocarrier stability. 
Surprisingly, we found that increasing the molar ratio of DSPE-PEG in the liposomes improved HPβ CD medi-
ated cholesterol efflux, and ultimately deduced that DSPE-PEG on its own triggered cholesterol clearance. Most 
remarkably, we found that DSPE-PEG used in combination with HPβ CD showed a substantial decline in the 
lysosomal cholesterol content in Npc1-deficient cells. These studies strongly suggest that a simple mixture of two 
well-characterized biocompatible excipients can have a significant impact in the treatment of NPC lysosomal 
storage disorder.
Results
A filipin-based assay was used to visualize accumulation of cholesterol in Npc1−/− MEFs. Filipin interacts with 
cholesterol to form a complex that is fluorescent at 405 nm. This assay has been utilized as a clinical diagnostic 
test for NPC disease and allows for rapid identification of molecules capable of sequestering cholesterol from 
intracellular membranes22,23. Using this assay, we confirmed heavy accumulation of cholesterol in enlarged punc-
tate structures inside Npc1−/− MEFs, relative to Npc1+/+ MEFs (Fig. 1A). To characterize these structures, we 
transfected both cell lines with Rab7-GFP, a late-endosome marker. Fluorescence microscopy revealed enlarged 
late-endosomes in Npc1−/− cells, with a clear demarcation of Rab7-GFP on the lysosomal surface. Filipin-stained 
cholesterol was observed within the lumen of Rab7-positive late-endosomes (Fig. 1B). In contrast, Npc1+/+ cells 
showed smaller Rab7-positive punctate structures, and the filipin stain appeared substantially lower and mark-
edly more diffused in the cytoplasm (Fig. 1B), suggestive of normal cholesterol transport in these cells. These 
studies confirm abnormal accumulation of cholesterol in late endo/lysosomes of Npc1−/− MEF cells.
We further utilized filipin imaging to demonstrate the well-documented use of HPβ CD to decrease intracellu-
lar cholesterol from endo/lysosomes in Npc1−/− cells, by cholesterol solubilization, which perhaps enables efflux 
from these intracellular depots. Npc1−/− cells show a marked decrease in filipin fluorescence with increasing 
concentration of HPβ CD treatment, up to 10 mM (Fig. 2A). Quantitative analysis of filipin staining shows that 
a 0.5 mM HPβ CD treatment for 24 hours reduced endosomal cholesterol by 50%. A 10 mM HPβ CD treatment 
further decreased cholesterol levels in Npc1−/− cells (ca. 75–80%), which is comparable to the levels in Npc1+/+ 
MEFs (Fig. 2B). In addition, we used an amplex-red assay to quantify cholesterol in whole cell lysates. We confirm 
a dose-dependent decrease in the total cholesterol in Npc1−/− cells (Fig. 2C).
We initially set out to encapsulate HPβ CD in the hydrophilic core of liposomes, formulated from HSPC 
and DSPE-PEG2k, in order to site-specifically deliver HPβ CD into the endo/lysosomal system. DSPE-PEG2k is 
a known liposomal stabilizer, and we tested liposomes composed of different molar ratios of these two lipids in 
order to optimize the formulation. Liposomes were assembled by thin film rehydration in the presence of a con-
centrated HPβ CD solution and dialyzed to remove free cyclodextrin. Liposomes were characterized for their size, 
shape, and encapsulation efficiency. We confirmed liposomal assembly using Transmission Electron Microscopy 
(TEM) imaging and measured their average hydrodynamic sizes using Dynamic light scattering (DLS). Both 
DLS and TEM showed that increasing PEG-lipid content decreased the size of the nanoparticles from 150 nm to 
10–15 nm (Fig. S1A,B). However, in formulations containing both lipid components, DLS suggested the presence 
of a mixed population of liposomes and micelles. We measured the loading efficiency using LC/MS/MS and 
found a gradual decrease in encapsulation with increasing PEG-lipid, which may be due to the increasing hydro-
phobic microenvironment of the core along with the decreasing size of the carrier. Surprisingly, when testing 
these formulations on Npc1−/− cells, the nanocarriers with higher molar ratios DPSE-PEG2k were the most potent 
in terms of cholesterol clearance despite a relatively lower loading efficiency of HPβ CD (Fig. S1C).
DSPE-PEG2k forms spherical micelles above the critical micelle concentration (CMC), of 1 μ M. DLS of 
assembled micelles showed a consistent and uniform 12 nm hydrodynamic size and TEM imaging showed a 
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5 nm electron dense core (Fig. 3A). This data is consistent with published models of PEG-lipid micelles that 
self-assemble to form a core-shell structure, in which the DSPE tail aggregates into a hydrophobic core and PEG 
chains are exposed to the aqueous solvent (Fig. 3B). To our surprise, treatment with only DSPE-PEG2k micelles 
resulted in a dose-dependent decrease in cholesterol levels in Npc1−/− cells (Fig. 3C,D). Treatments as low as 1 μ 
M DSPE-PEG2k led to 13% reduction in cholesterol, which, when increased to 10 μ M, resulted in a ~40% reduc-
tion in cholesterol. The 40% reduction was the highest cholesterol egress achieved, even with concentrations up 
to 500 μ M. This decrease was significant, since a 75–80% reduction of cholesterol in Npc1−/− cells reduced cho-
lesterol to normal cellular levels (Fig. 2B,C). Both filipin and amplex red cholesterol assays show similar results, 
which strongly suggests that these materials are capable of reducing intracellular cholesterol deposits and enabling 
cholesterol efflux from the endo/lysosomal system.
DSPE-PEG2k is an essential component of LNPs that have been shown to preferentially accumulate in the 
late endosomes/lysosomes of Npc1−/− cells. Therefore, we hypothesized that DSPE-PEG2k actively accumulates 
in these cells and subsequently leads to solubilization of cholesterol. To test this hypothesis, we evaluated the 
uptake kinetics of carboxy-fluorescein (CF) labeled DSPE-PEG2k micelles at different time points and moni-
tored their localization within filipin-positive late-endosomes using automated high-throughput imaging. The 
DSPE-PEG2k-CF was detected by cellular internalization after approximately 2 hours, and saturated the endo/
lysosomal system within 24 hours; the relatively slow rate of uptake is suggestive of macropinocytosis (Fig. 4A,B). 
We utilized filipin to measure localization of DSPE-PEG2k-CF delivered to the cholesterol-rich late endosomes/
lysosomes in Npc1−/− cells. At 2 hours, the labeled micelles show ~50% co-localization with filipin-stained 
Figure 1. Npc1 deficiency leads to cholesterol accumulation in enlarged late endosomes/lysosomes.  
(A) Filipin staining was performed to visualize subcellular cholesterol in Npc1−/− and Npc1+/+ MEFs. A high 
throughput microscope was used to compare subcellular cholesterol (psuedo colored red) in both cell types. 
Nucleus was stained using HCS nuclear mask deep red stain. (psuedo colored blue) (B) Npc1−/− and Npc1+/+ 
MEFs were transfected with to Rab-7 GFP (pseudo colored green) using a baculovirus. Cells were fixed 18 hours 
post transfection and stained with filipin (red). The cell outline is demarcated with dotted line; white arrow 
shows filipin and black arrow endosomal Rab7-GFP. All experiments were conducted in triplicates.
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cholesterol deposits (Fig. 4C) but within 4–6 hours ~60% of the labeled micelles reached filipin-positive endo-
somes and by 24 hours we observed an 80% co-localization with late endosomes/lysosomes (Fig. 4C). These 
studies clearly show a substantial delivery of DSPE-PEG2k-CF micelles into the cholesterol-laden endo/lysosomes 
of Npc1−/− cells. It is likely that DSPE-PEG interacts with large cholesterol deposits in the late endosomes, which 
leads to a degree of aggregate solubilization and potentially releases them from the lysosomal compartment. 
Interestingly, DSPE-PEG2k-CF did not show enhanced accumulation in wild-type cells (data not shown), sugges-
tive of enhanced accumulation in late-endosomes due to recycling defects present in Npc1−/− cells as previously 
observed21.
We set out to evaluate the synergy of combinatorial treatments with both DSPE-PEG and HPβ CD to potentiate 
cholesterol removal. We created a matrix of treatment groups consisting of DSPE-PEG2k micelles (0.05–500 μ M) 
and HPβ CD ranging from 0.01 mM–10 mM. Npc1−/− cells were exposed to these treatments, in combi-
nation or alone, for 24 hours, prior to fixing, staining and imaging (Fig. 5A). Quantification of filipin flu-
orescence showed a decrease in cholesterol with individual treatments, and a synergistic effect when both 
treatments were administered together (Fig. 5B). We observed that a treatment of 0.05 mM HPβ CD and 5 μ M 
DSPE-PEG2k showed a 30% cholesterol clearance, which was further reduced to 50% with 0.05 mM HPβ CD and 
10 μ M–100 μ M DSPE-PEG2k treatment. This effect became more pronounced as the concentration of each com-
ponent was increased. A 75% cholesterol reduction resulted from treatment of 0.25 mM of HPβ CD combined 
with 10 μ M DSPE-PEG2k, making cholesterol levels comparable to wild-type cells. It has been observed that a 
dose of 1 mM HPβ CD in Npc1 mutant neuronal cultures or in plasma of human patients elicits a drug response 
that affects the disease phenotype8,24. We showed that 1 mM HPβ CD reduces cholesterol by ~50%, but a com-
parable cholesterol reduction can be achieved with 10 μ M DSPE and a 4-fold lower concentration of HPβ CD 
Figure 2. HPβCD removes cholesterol from Npc1−/− cells. Npc1−/− MEFs were incubated with HPβ CD 
(0–10 mM) for 24 hours. Cells were either fixed or lysed. (A) Fixed cells were imaged for filipin stain using high 
throughput imaging and representative images are show for 0.01, 0.1, 1 and 10 mM HPβ CD treatments. (B) Filipin 
fluorescence per cell was quantified using Olympus scanR analysis software, and normalized to untreated 
cells. 48 images per treatment group were analyzed. (C) Cell lysates were analyzed for total cellular cholesterol 
using the amplex red assay and normalized by total protein content. Untreated Npc1+/+ MEFs are shown 
for comparison. Results were tested for statistical significance using one-way ANOVA with Tukey’s multiple 
comparison test. * P < 0.05, * * P < 0.01, * * * P < 0.001 and NS = not significant.
www.nature.com/scientificreports/
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(0.05 mM). We observed no toxicity at these concentrations, and only at an exceptionally high treatment combi-
nation i.e. 10 mM HPβ CD and 500 μ M DSPE-PEG2k, there was a dramatic reduction in total cell number (Fig. S2).
PEG-lipids are commercially available with various PEG chain lengths, and we tested a diverse set that included 
DSPE-PEG350, DSPE-PEG1k, DSPE-PEG2k, DSPE-PEG5k, DSPE-PEG10k, DSPE-PEG20k, and DSPE-PEG30k at 10 μ M 
both with and without 0.1 mM HPβ CD (Fig. 6A). DSPE (unconjugated), DSPE-PEG350 and DSPE-PEG1k treat-
ments did not decrease cellular cholesterol. On the other hand, DSPE-PEG2k, DSPE-PEG5k, DSPE-PEG10k, 
DSPE-PEG20k, and DSPE-PEG30k showed cholesterol reduction where longer PEG chain lengths performed 
marginally better relative to shorter chain lengths. The co-treatment of low dose DSPE-PEGs with 0.1 mM HPβ 
CD further reduced cellular cholesterol in most treatments. Interestingly, treatment with PEG2k or combina-
tion treatment of PEG2k and DSPE (unconjugated) showed increased cholesterol accumulation in Npc1−/− cells 
(Fig. 6A, S3). We observed that as the PEG chain length increases the size of the micelles also increase from 
5 nm (DSPE-PEG350) to 24 nm (DSPE-PEG10–30k). Micelles with the hydrodynamic size of 16–24 nm, independ-
ent of PEG chain length, were capable of equivalent cholesterol efflux suggesting that this size range is important 
for access to lysosomal pathways (Fig. 6B). We further tested if other polymers with micelle forming capacity 
can cause cholesterol clearance. Pluronic block copolymers are composed of poly (ethylene oxide) (PEO) and 
poly(propylene oxide) (PPO) segments, that above CMC self assemble as micelles with hydrophobic PPO cores 
and hydrophilic PEO shell. These polymers have the ability to solubilize drugs for cellular internalization and 
Figure 3. DSPE-PEG2k reduces cellular cholesterol in Npc1−/− cells with a dose dependent response. 
DSPE-PEG2k micelles were assembled by thin film rehydration method. (A) TEM images of micelles show 
electron dense cores that are approximately 5 nm. (B) Schematic diagram of assembled DSPE-PEG2k micelles 
has an electron dense hydrophobic core, with extended hydrophilic PEG head groups. (C) Npc1−/− cells were 
exposed to different concentrations of DSPE-PEG2k (0–500 μ M), fixed and a dose dependent decrease in filipin 
fluorescence per cell was observed by high throuhgput screening. (D) Whole cell cholesterol (per mg protein), 
normalized to un-treated cells, also shows a dose dependent reduction in cholesterol when treated with DSPE-
PEG2k. Results were tested for statistical significance using one-way ANOVA with Tukey’s multiple comparison 
test. * P < 0.05, * * P < 0.01, * * * P < 0.001 and NS = not significant.
www.nature.com/scientificreports/
6Scientific RepoRts | 6:31750 | DOI: 10.1038/srep31750
have been used extensively to deliver various drugs25. Pluronic block copolymers interact with cholesterol sub-
domains within lipid rafts in cellular membranes and cause membrane fluidization26. We tested whether a set of 
block copolymers including L64, P84, P103 and F127 containing 30, 39.7, 59 and 65.2 number of respective PPO 
blocks would affect cholesterol efflux. We observed effects on cholesterol clearance with F127 at 1.5 mg/ml, which 
is an exceptionally high dose. The other polymers had showed toxicity at a high dose in Npc1−/− cells (Fig. S4).
Figure 4. Labeled DSPE-PEG2k is internalized and localized to filipin positive vesicles in Npc1−/− cells. 
Carboxy-Fluorescein (CF) labeled DSPE-PEG2k assembled into micelles by thin film rehydration was exposed 
to cells at 10 μ M concentration for different time points (2, 3, 4, 6, 24 hours), cells were washed, fixed and filipin 
stained. (A) High throughput imaging (16 images/well) was performed to monitor DSPE-PEG2k-CF uptake 
and co-localization with endosomal cholesterol. (B) Image-J software was utilized to measure DSPE-PEG2k-CF 
uptake and (C) Monitor co-localization by calculation of Pearson Coefficient. (n = 5). Results were tested for 
statistical significance using one-way ANOVA with Tukey’s multiple comparison test relative to untreated cells 
(B) or 24 hour treated cells (C). * P < 0.05, * * P < 0.01, * * * P < 0.001 and NS = not significant.
www.nature.com/scientificreports/
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Autophagy, a catabolic process that directs cytosolic components towards the lysosomes for degradation, has 
been suggested to be dysregulated in lysosomal storage disorders27. It has been shown that Npc1−/− cells have a 
block in autophagic flux that leads to accumulation of toxic components within the cells28. We evaluated auto-
phagic activity using Npc1−/− and Npc1+/+ MEFs that stably express a doxycycline-inducible firefly luciferase-p62 
construct (p62-fluc). p62 acts as a marker for cellular cargo that is specifically degraded by autophagy. Therefore, 
higher luciferase expression corresponds to lower autophagic degradation. In Npc1+/+ MEFs there was a little if 
any retardation in the degradation of p62-fluc with increasing concentrations of DSPE-PEG without any signif-
icant effect on cell viability when treated for 24 hours and 48 hours (Fig. 7A,C). We then analyzed the effect on 
autophagy in Npc1−/− MEFs treated with DSPE-PEG. While, we did not observe a change in p62 degradation in 
24 hours post treatment (Fig. 7B) a dose-dependent decrease in p62-fluc degradation was seen with DSPE-PEG 
treatment after 48 hours, without any substantial effect on cell viability (Fig. 7D). We treated Npc1−/− MEFs for 
24 hours with a combination of 0.25 mM or 1 mM HPβ CD and between 0.1 and 100 μ M DSPE-PEG. We observed 
that the combinations at these doses did not substantially exacerbate autophagy (Fig. 7E,F). To further investigate 
the effect of DSPE-PEG and HPβ CD treatment on the autophagic flux we used Npc1−/− and Npc1+/+ MEFs that 
stably express a tandem fluorescent-tagged LC3 reporter, TF LC3 (mRFP-EGFP-LC3). LC3 is a specific marker 
of autophagosomes since it is present on autophagosomal membrane from their formation until degradation in 
Figure 5. Combination treatment of PEG-lipid and HPBCD lead to synergistic clearance in Npc1−/− cells. 
Npc1−/− MEFs cells were treated with DSPE-PEG2k micelles (0–500 μ M) and HPβ CD (0–10 mM). Cells were 
fixed and stained with filipin and nuclear mask. (A) Representative images of select treatments are shown and 
illustrate the synergistic cholesterol reduction of the two treatments. (B) Cells were quantitatively analyzed 
for filipin fluorescence per cell, and the dose dependent reduction of filipin fluorescence is shown normalized 
to untreated cells. Images per well were taken (n = 3, 16 images/well) and cells were quantified for total filipin 
fluorescence. The treatment with 500 μ M DSPE-PEG2k and 10 mM HPβ CD is toxic, and no cells are observed. 
Results were tested for statistical significance using one-way ANOVA with Tukey’s multiple comparison test.  
* P < 0.05, * * P < 0.01, * * * P < 0.001 and NS = not significant.
www.nature.com/scientificreports/
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autolysosomes29. Coupling LC3 with mRFP and EGFP gives us the ability to distinguish between autophagosomes 
(mRFP+/EGFP+) and autolysosomes (mRFP+/EGFP−) as EGFP is acid-labile and therefore its signal is quenched 
in autolysosomes. We noted an increased number of autophagosomes and decreased number of autolysosomes in 
the Npc1−/− MEFs compared to Npc1+/+ MEFs (Fig. 8A), suggestive of an impairment in autophagy in NPC1 dis-
order, as previously described28. A combination of 0.25 mM HPβ CD and 10 μ M DSPE-PEG, compared to 10 μ M 
DSPE-PEG alone had no effect on the percentage of autophagosomes and autolysosomes (Fig. 8B). However, 
there was a decrease in the overall number of autophagosomes and autolysosomes (Fig. 8C) upon exposure of 
these admixtures, although this difference did not translate into defects of p62 clearance (Fig. 7), which suggests 
that this combination may have an effect on the dynamics of autophagic vesicles without exacerbating defects in 
autophagic cargo clearance. Overall, these studies indicate that low dose combination treatment with these mole-
cules to enable cholesterol efflux, do not worsen the defects in autophagy prevalent in Npc1−/− cells.
Discussion
PEG-conjugated lipids are used extensively in the field of drug delivery as excipients30. DSPE-PEGs are biocom-
patible, biodegradable and have been a component of several nanoparticle platforms for drug or nucleic acid 
delivery that are undergoing clinical trials30–33. The liposomal formulation Doxil contains DSPE-PEG as one of 
its constituents and has been clinically approved for use against ovarian cancer and AIDS related Kaposi sar-
coma34. DSPE anchors PEG to the surface of these liposomes, which forms a protective hydrophilic coating that 
maintains stability of the nanoparticles. PEGylation of nanoparticles mitigates binding to serum proteins, which 
provides certain stealth effects, as nanoparticles evade recognition and opsonization by macrophages and pro-
longs circulation time17,35,36. Tuning PEG density at the surface of nanocarriers allows delivery across biological 
barriers, e.g. high PEG density assists in traversing mucosal barriers and can also enable widespread distribution 
in the CNS tissue once injected directly into the brain37,38. PEG-lipids are amphiphilic by nature and at low con-
centrations exist as single-coil unimers; above the CMC PEG-lipids form micelles with a core-shell morphology. 
The hydrophobic core can solubilize hydrophobic drugs, while the shell interacts with the aqueous serum envi-
ronment39. The derivitization of PEG-lipids allows liposomal surface decoration of a repertoire of ligands for the 
Figure 6. PEG chain length in DSPE-PEG micelles affects cholesterol reduction in Npc1−/− cells.  
(A) Npc1−/− MEFs were treated with DSPE-PEG micelles (10 μ M) with increasing PEG chain length in the 
presence or absence of low dose HPβ CD (0.1 mM). Cells were washed and stained for filipin. (A) Longer PEG 
chain lengths (> 2,000 MW) show effective cholesterol reduction when treated with 10 μ M. Micelle treatment 
with 0.1 mM HPBCD additionally reduces cholesterol when administered with DSPE-PEG micelles. (B) DLS 
was used to calculate average diameter of DSPE-PEG micelles, data is reported as distributed by number. Results 
were tested for statistical significance using one-way ANOVA with Tukey’s multiple comparison test. * P < 0.05, 
* * P < 0.01, * * * P < 0.001 and NS = not significant.
www.nature.com/scientificreports/
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purposes of tissue targeting. These conjugates have been even used to tether ligands on the surface of cells for 
ex vivo therapies40. DSPE-PEG micelles have been explored as carriers for diagnostic imaging agents, and have 
been safely injected into mice with a detected circulation concentration of greater than 1 mM, three orders of 
magnitude above the CMC41. These studies, to the best of our knowledge, for the first time reveal that DSPE-PEG 
can have the ability to preferentially accumulate inside the late endosomes of Npc1−/− cells and remove cholesterol 
from the endo/lysosomal system.
The NPC1 protein is a cholesterol efflux transporter that shunts cholesterol from the late endosomes to the 
endoplasmic reticulum42. Functional absence of NPC1 results in lipid accumulation in late endosomes/lyso-
somes. We observed cholesterol aggregates sequestered in the lumen of Rab7 positive late endosomes. Cholesterol 
aggregation results in cytotoxicity of neurons and hepatocytes due to their high sensitivity towards lipid accumu-
lation5. Furthermore, the absence of NPC1 was shown to downregulate caveolae/lipid raft-mediated endocytosis 
while other entry pathways, such as macropinocytosis and clathrin-mediated endocytosis, remained intact43,44. 
Moreover, it was discovered that biodegradable nanoparticles that utilize caveolae/lipid-raft based micro-domains 
to enter cells fail to internalize and deliver DNA in Npc1−/− cells, while LNPs that enter cells using macropino-
cytosis show a high retention due to defects in their recycling in Npc1−/− cells that translate to effective siRNA 
delivery at very low doses21. Interestingly, this study shows similar retention of DSPE-PEG in late endosomes/
Figure 7. DSPE-PEG treatment slightly reduces autophagic degradation in Npc1+/+ and Npc−/− MEFs 
(A,C) p62-fluc.Npc1+/+ and, (B,D) p62-fluc. Npc−/− MEFs were induced to accumulate p62-fluc fusion protein 
with 1 μ g/ml of Doxycycline for 24 hours. Doxycycline was washed from the cells and then they were treated 
with 0–100 μ M DSPE-PEG2k for 24 (A and B upper panels) or 48 (C and D, upper panel) hours and autophagic 
degradation was measured using luciferase intensity. The cells were also analyzed for cell viability (lower panels). 
(E,F) Npc1−/− p62-fluc were also treated with a combination of HPβ CD (0.25 mM or 1 mM, respectively) and 
DSPE-PEG (0–100 μ M) for 24 hours after being induced for 24 hours with 1 μ g/ml of Doxycycline. Results were 
tested for statistical significance using one-way ANOVA with Tukey’s multiple comparison test. * P < 0.05,  
* * P < 0.01, * * * P < 0.001 and NS = not significant.
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lysosomes through a striking co-localization with filipin, which suggests that these nanocarriers possibly interact 
with cholesterol in the closed microenvironment of the late-endosomes and promote cholesterol solubilization. 
We speculate that within the DSPE-PEG construct, the DSPE serves to integrate into the cell membrane to enter 
cells and further interacts with the hydrophobic sterol aggregates promoting solubilization while the PEG chains 
interact with the hydrophilic glycocalyx that surrounds the lumen of the lysosomes45, enabling cholesterol efflux 
from these compartments. DSPE-PEG has been shown to stimulate cholesterol release from synthetic donor 
liposomes; perhaps such cholesterol release occurs in the multi-vesicular late endosome as well46. It is possible 
that the presence of DSPE-PEG triggers the formation of liposomal structures in situ that disassembles cho-
lesterol/lipid aggregates, with the PEG chain lining the surface of the liposome to promote transfer across the 
lysosomal luminal membrane. PEGs exist in brush or mushroom conformations dependent on chain length, 
when assembled onto a nanocarrier surface47, and whether these conformations form within the confines of the 
endosomal microenvironment remains to be tested. It is also possible that among the different PEG-lipids, a par-
ticular size range may play an important role in targeting nanocarriers precisely to the endosomal compartment 
that requires cholesterol sequestration.
NPC is a devastating disease for which no treatment is available in the United States. There is a tremendous 
excitement among scientists for a solution for this disease as preclinical animal models and patients respond 
positively to HPβ CD treatment. Yet, the relatively high dose required to achieve therapeutic response has been 
associated with hearing loss that occurs due to interaction of HPβ CD with prestin, a protein located on outer-hair 
cells of the cochlea48. To overcome these issues of efficacy, new polymers such as Pluronic/β -cyclodextrin 
Figure 8. The effect on autophagic flux by DSPE-PEG and HPβCD combination treatment. TF.LC3.Npc1+/+ 
and TF.LC3.Npc1−/− MEFs were treated for 24 hours with 10 μ M DSPE-PEG2k, 0.25 mM HPβ CD or the 
combination of the two chemicals. Cells were then fixed, counterstained with DAPI and imaged at 100x 
magnification. (A) Representative images showing EGFP signal (far-left panel), mRFP signal (mid-left panel), 
merged EGFP and mRFP (mid-right panel) and colocalization of EGFP and mRFP (far-right panel). Scale 
bar = 20 μ m. Images were quantified using ImageJ software. Quantification of microscope images showing the 
(B) number of autophagosomes and autolysosomes as a percentage or as (C) total number. Results were tested 
for statistical significance using two-tailed student’s t-test. * P < 0.05, * * P < 0.01, * * * P < 0.001 and NS = not 
significant.
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polyrotaxanes have been synthesized to release multiple cyclodextrin molecules in the reducing endosomal 
environment49–51. Unfortunately these new compounds will require extensive preclinical and clinical testing 
prior to translational development. HPβ CD, at high doses, exacerbates autophagy defects; on the other hand, 
repeated administration of PEG has been associated with complement activation28,52 and perhaps by combining 
DSPE-PEG and HPβ CD a synergistic response at low doses can promote cholesterol egress without causing tox-
icity. It has been observed in Npc1−/− cats that a 120 mg of intra-cisternal dose of HPβ CD increased survival from 
22 weeks to 76 weeks to 4 years12, and it is therefore, tempting to speculate that injecting admixtures of cyclodex-
trin with DSPE-PEG, directly into the brain will lower the dose necessary for survival and decrease the substantial 
side effects of HPβ CD, otherwise observed in clinical and preclinical models of NPC disorder.
Liposomes with increasing amounts of PEG-lipids were developed for encapsulation and co-delivery of HPβ 
CD, and we observed that the liposomal size decreased from roughly 100 nm to 10–20 nm as the PEG-lipid molar 
ratio increased. Nanoparticles transition from an aqueous core encapsulated in a lipid bilayer to a micelle with 
a hydrophobic core with increasing molar ratios of DSPE-PEG, thus decreasing the encapsulation efficiency of 
the hydrophilic drug. We observed that when treatments were normalized for HPβ CD concentrations and con-
stant lipid concentrations, the nanocarriers with higher DSPE-PEG content resulted in substantial cholesterol 
clearance, and DSPE-PEG micelles were the most potent. PEG-lipid micelles or liposomes with high amounts 
of DSPE-PEG might serve as bioactive drug delivery agents for treatment of NPC. We were further able to test 
whether other polymers have the ability to egress cholesterol. We tested a set of Pluronic block copolymers that 
have the capability to self-assemble as micelles. Pluronic micelles utilize clathrin-mediated endocytosis to access 
endo/lysosomes and modulate cholesterol fluidity to inhibit drug efflux transport, activate gene expression, and 
induce dose-dependent hyperlipidemia25,53. Among the materials tested, Pluronic F127 showed an effect at very 
high concentrations, suggesting that some of these surfactants might cause non-specific cholesterol clearance.
There are several new strategies for potential therapeutics against NPC disease that may require nanocar-
rier based drug delivery systems. Vironosotat, a histone deacetylase inhibitor (HDACi) has been shown to clear 
cholesterol in human patient fibroblasts carrying the NPC1I1061T mutation54,55. HDACi inhibitors enhance tran-
scriptional activity; overexpression partially compensated for the NPC1I1061T mutation and acts as a chaperone to 
untangle mis-folded protein. HPβ CD has recently been used to solubilize the hydrophobic vironosat, and when 
administered subcutaneously to NPC1I1061T mutant mice, substantially improved life span56. However, this for-
mulation consists of high amounts of cyclodextrin and 5% DMSO, a toxic organic solvent that could limit clinical 
applicability56. Carbamazepine an autophagy inducer used to overcome the autophagy blockade57 and remove 
toxic cytosolic debris, will be an important ingredient in the formulation for treatment of NPC28. PEG-lipid 
micelles can entrap hydrophobic drugs, such as vironostat or carbamazepine in the core, and when formulated 
with cyclodextrin could result in a potent drug combination against NPC. As new variants of cyclodextrin that 
have different degree of substitutions are identified for improved efficacy and reduced ototoxicity in NPC disease, 
these agents can be replaced in the aforementioned drug cocktail58. Additionally genetic editing and gene delivery 
approaches have been used to correct mutated genes, including Npc1, which offers a precise treatment and poten-
tial cure for rare genetic disorders and can benefit from non-viral delivery technologies19,59. Finally, traversing 
the blood brain barrier is required for successful translation of this technology, and we anticipate modification of 
these nanocarriers with multivalent targeting ligands for brain delivery60. Potentially attaching new brain shuttle 
technologies that have shown to enhance brain penetration in different animal models, including non-human 
primates, or temporary opening of the blood- brain barrier will enable brain targeting61,62. This information 
serves as a blueprint to further develop PEG-lipid based bioactive nanocarriers with brain targeting capability 
that can exploit trafficking defects to site-specifically deliver drugs or their combinations for effective treatment of 
NPC. Taken together, nanocarriers can serve as a platform that can effectively deliver small molecules, genes and 
perhaps imaging agents for treatment and diagnosis of a wide variety of other rare lysosomal storage disorders.
Materials and Methods
Assembly of Liposomes or Micelles. Liposomes were formed using the thin film rehydration method. 
Briefly HSPC (Avanti Polar Lipids), DSPE-PEG2k (NOF America) or a combination, were dissolved in ethanol 
at 20 mM. To make thin films, 2 μ Mol of lipid was dried in 20 mL glass scintillation vial (approximately 1 in2) 
under vacuum and rehydrated by sonication for 20 mins at 40 °C in a bath sonicator. Liposomes were formed in 
200 μ L of 400 mM HPβ CD (ACROS Organics) in PBS. Clean DSPE-PEG2k micelles were assembled in 200 μ L 
Opti-MEM and cooled on ice until further use. Liposomes were washed twice in PBS to remove unencapsu-
lated HPβ CD using a centrifugal filter concentrator (Amicon Ultra− 15 10 k MWCO) for 10 minutes at 17 k × G. 
Assembled micelles (without HPβ CD) were diluted as necessary to be used in cell treatment studies. Additional 
lipid micelles, including DSPE, DSPE-PEG350, DSPE-PEG1k, DSPE-PEG5k or DSPE-PEG2k-CF (Avanti-Polar 
lipids) and DSPE-PEG10k, DSPE-PEG20k, DSPE-PEG30k, (Creative PEGWorks) were formed from lipid stocks 
stored in chloroform. Thin films (100 nmoles lipid) were formed as described above and hydrated in 100 μ L Opti 
MEM to make 1 mM stock solutions. For PEG2k a 10 μ M solution was made from powder rehydrated in Opti 
MEM, and diluted to desired concentrations. Pluronics P84 (Sigma Aldrich), L64, F127 and P103 (BASF SE) were 
diluted from stock solutions (150 mg/mL) in Opti MEM for cell treatments as described above.
Materials Analysis. Liposomes or micelles were confirmed using dynamic light scattering (Malvern 
Zetasizer) in PBS and average size is reported based on a number distribution. Transmission Electron Microscopy 
(TEM) was performed on an FEI Tecnai F-20 TEM operating at 200 kV. Samples of liposomes or micelles were 
prepared by drop casting onto a carbon coated copper grid (Ted Pella), and allowed to air dry. HPβ CD was meas-
ured using an adapted LC-ESI-MS/MS method63. Briefly, washed liposomes were digested in methanol and sub-
jected to high-performance liquid chromatography (HPLC)-tandem mass spectrometry using a 75 × 2 mm C18 
3 μ m particle LC column (Phenomenex Torrance, CA) coupled to a SCIEX 4000 QTRAP LC/MS/MS equipped 
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with a electrospray ionization (ESI) source operating in the positive mode. The HPLC column temperature was 
kept at 40 °C. Analyte and internal standard (methyl-β -cyclodextrin) were resolved using a gradient method 
with solvents A (methanol at 0.1% formic acid) and B (100 mM ammonium formate) at a flow rate of 0.5 ml/min 
changed as follows: 5% to 95% B over 1 minute, held at 95% B for 1.5 minutes and equilibrated at 5% B for 
2.5 minutes. The ESI ion source parameters were as follows: 48 V collision energy, 30 units curtain gas, 5000 V ion 
spray, 450 C temperature, 40 units gas 1 and 50.00 gas 2. Multiple reaction monitoring mass transitions scanned 
for 100 msec were m/z 1307 → 367.4 for methyl-β -cyclodextrin, and m/z 1385 → 383.4 and 1443 → 383.4 for 
HPβ CD. HPβ CD and internal standard had a retention time of approximately 1.7 minutes. Calibration curves 
for quantification were created using HPβ CD standard across the concentration range 0.05–500 μ g/ml with 
methyl-β -cyclodextrin at 25 μ g/mL. The area ratio of analyte to internal standard was plotted against the nom-
inal concentration for calibrators and a quadratic regression analysis was used to calculate the concentration in 
unknown samples.
Imaging. Npc1−/− and Npc1+/+ immortalized mouse embryonic fibroblasts (MEFs) (kind gifts from the 
Langer Lab at MIT) were cultured in DMEM/10% FBS at 37 °C. Cells were plated into a 96 well plate (4 k cell/well 
with 100 μ L media) and allowed to settle for 24 hours. Intracellular staining of cholesterol in these cells was per-
formed using filipin staining of paraformaldehyde fixed cells. Cells were washed in PBS and 2 mM Glycine in PBS 
for 10 minutes, prior to staining with 0.05 mg/mL, filipin complex (Sigma Aldrich) in 10% FBS for 2 hours. Cells 
were then washed in PBS three times and stored in 100 μ L PBS with 1x HCS NuclearMask Deep Red Stain (Life 
Technologies) at 4 °C for further analysis. Npc1−/− cells were treated with drug (HPβ CD), PEG-lipid or a com-
bination of drug with PEG-lipid, dissolved in Opti-MEM (Thermo Fisher). After a 24-hour incubation, media 
was removed, cells were washed in PBS and fixed in 4% paraformaldehyde at room temperature for 20 minutes, 
followed by filipin staining. Reduction of filipin staining from the lysosomal stores of Npc1−/− cells is referred as 
cholesterol efflux. For Rab7-GFP (marker of late endosomes) experiments, Npc1+/+ or Npc1−/− cells were each 
transfected with Rab7-GFP using a baculovirus (Bacmam 2.0) for 18 hours, fixed and filipin stained as described, 
and imaged. For uptake and localizationstudies,1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[poly(eth-
ylene glycol)-2000-N′-carboxyfluorescein] (Avanti Polar Lipids) (DSPE-PEG-CF) were assembled into micelles 
(described below) and incubated with cells for specified time points prior to fixing and filipin staining. High 
throughput imaging was performed using either an automated high-throughput fluorescence microscope 
(Olympus scanR) at 20X with at least 16 images/well were analyzed using the Olympus scanR analysis software. 
In select cases, EVOS FL Auto Cell imaging system (Invitrogen) 20X or 40X was utilized. All experiments were 
performed in triplicates and errors are reported as S.E.M.
Total cellular cholesterol from cell lysates. Amplex Red cholesterol assay (Amplex Red Cholesterol 
Assay Kit, ThermoFisher) was performed according to manufacturers instructions and used to quantify total cel-
lular cholesterol from cell lysates, which was normalized to total protein content using the Bradford Assay. Briefly, 
after drug treatments, cells were washed with PBS and lysed with Cholesterol Mammalian Protein Extraction 
Reagent (ThermoFisher Cat # 78501). The cells were frozen for 10 mins at − 80 °C and plates were thawed for 
30 mins at 37 °C. The cell lysates were treated with Amplex red reagent (prepared using Manufacturers protocol) 
in presence of Halt Protease inhibitor (Halt™ Protease and Phosphatase Inhibitor Cocktail, EDTA-free (100X), 
ThermoFisher Cat # 78445). Cell lysates were incubates at room temperature for 1 hr and fluorescence (Ex/
Em = 540/590) was measured using Tecan Microplate reader (Tecan). The cell lysates were treated with Bradford 
reagent (Pierce™ Coomassie (Bradford) Protein Assay Kit, (ThermoFisher) and their absorbance (595 nm) was 
measured. Standard curves were plotted using known concentrations of Cholesterol (Amplex Red assay) and 
Bovine Serum Albumin (Bradford) to interpolate cell lysates based data. All experiments were performed in 
triplicates and errors are reported as S.E.M.
Cloning and generation of stable cell lines. p62-Lucifearse expressing Npc1 stable cell lines. Npc1+/+ 
and Npc1−/− MEFs were transduced with a doxycycline inducible p62-firefly luciferase (p62-fluc) construct that 
also had a puromycin resistance gene were maintained in 1 μ g/ml puromycin (Sigma-Aldrich P8833). Briefly, the 
doxycycline inducible pCW57.1 backbone was purchased from Addgene (41393). Gibson assembly was used to 
insert firefly luciferase (Fluc) and p62 into the pCW57.1 backbone. Fluc, p62 and pCW57.1 were PCR amplified 
using pfu polymerase (Life technologies) and Gibson assembly primers with 20 bp overhangs. PCR products 
were separated by agarose gel electrophoreses, and fragments excised and purified before use in DNA assembly 
reaction with the NEBuilder HiFi DNA Assembly kit (New England Biolabs) according to the manufacturer’s 
instructions. After the assembly, the reaction mix was transformed into NEB3040 NEB Stable Competent E. coli 
(New England Biolabs). After 24 h growth at 31 °C the plasmid was extracted using QIAprep Spin Miniprep Kit 
(Qiagen). The plasmid was sequenced to confirm correct insertion of Fluc-p62. To generate Npc1+/+ and Npc1−/− 
MEFs stably expressing doxycline inducible Fluc-p62, HEK293FT cells were transfected with Fluc-p62-pCW57.1 
and the ViraPower Packaging Mix (Invitrogen) to produce lentivirus. Npc1+/+ and Npc1−/− MEFs were trans-
duced with the obtained lentiviral stock followed by selection with 1 μ g/ml puromycin.
Gibson primers: pCW57.1FW-AGCATCCCCCGCCGTTGTGATTCTTGTACAAAGTGGTTTA 
GTAATGAACCGGTCCA pCW57.1 REV-ATGTTTTTGGCGTCTTCCATTGATGCTAGCCAAT 
TC TC C AG G C G ATC  f i re f ly  lu c i fe r a s e F W- TG G AG A AT TG G C TAG C ATC A ATG G A AG AC 
GCCAAAAACATAAAGAAAGG firefly luciferase REV-TTCACGGTGAGCGACGCCATCACGG 
CGATCTTTCCGCCCT p62 FWD-GAAAGATCGCCGTGATGGCGTCGCTCACCGTGAAGGCCTACCTTC 
p62 REV-TAAACCACTTTGTACAAGAATCACAACGGCGGGGGATGCTTTGAATACTGGA.
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Tandem Fluorescent LC3 expressing Npc1 stable cell lines. Npc1+/+ and Npc−/− MEFs were transduced with a 
tandem-fluorescent LC3 reporter (TF-LC3 (mRFP-EGFP-LC3)) which also contained a puromycin resistance 
gene. MEFs were selected with 1 μ g/ml of puromycin. After 1 week of selection the cells were plated as single cells 
in a 96 well plate to generate monoclonal TF-LC3 lines. pLenti-Synapsin-hChR2(H134R)-EYFP-WPRE (pur-
chased from Addgene (20945)) was digested with PacI and EcoRI enzymes. TF-LC3 and IRES-PURO were ampli-
fied using PCR with Q5 HighFidelity DNA Polymerase (NEB) using Gibson Assembly primers, which contained 
15bp overhangs. Purified amplicons were mixed and assembled using Gibson Assembly Master Mix (NEB). The 
assembled DNA was transformed into NEB® 5-alpha Competent E. coli (NEB). DNA was amplified in E. coli and 
sequenced to check for correct insertion of the TF-LC3 and the puromycin resistance gene. Then plasmid DNA 
was transfected into 293T cells with lentiviral packaging plasmids (tat, rev, gag/pol and vsv-g). Lentiviral particles 
were collected after 24 hours and used to transduce Npc1+/+ and Npc−/− MEFs.
Gibson primers:TF-LC3-F – AGATCCAGTTTGGTTAATACCATGGCCTTCTCCGAG TF-LC3-R – 
CCATCTTCCTGTCACAAGCATGGCTC IRES-PURO-F – TGTGACAGGAAGATGGCGATTAGAGATCC 
IRES-PURO-R – CGATAAGCTTGATATCGGATTTAGGCACCGGGCTTGC.
Luciferase Assay. First, the p62-fluc.Npc1+/+ and p62-fluc.Npc1−/− MEFs were plated into white 96 well 
plates (2 k cell/well with 100 μ L media) and allowed to settle for 24 hours. Next, the MEFs were treated with 1 μ 
g/ml doxycycline (Sigma-Aldrich 33429) for 24 hours before being washed off 3 times with PBS. Subsequently, 
the specified drug or a combination of drugs was dissolved in Opti-MEM (Thermo Fisher) and all of media was 
removed from cells and replaced with DSPE-PEG2k containing media and incubated for 24 hours. MEFs to be 
treated for 48 hours with the micelles were aspirated after 24 hours and fresh DSPE-PEG2k media was added for 
the final 24 hours. After 24 hours or 48 hours of drug treatment, MEFs were analyzed using ONE-Glo™ + Tox 
Luciferase Reporter and Cell Viability Assay (Promega) by following the manufacturer’s protocol.
TF.LC3 analysis. Analysis of autophagosome maturation using mRFP-EGFP-LC3 (TF-LC3) reporter was 
performed in the following way. TF-LC3.Npc1+/+ and TF-LC3.Npc−/− MEFs were plated onto 9 mm glass cov-
erslips coated with 0.2% gelatin (Sigma) at a density of 25000 per coverslip. The following day the cells were 
treated with for 24 hours with 10 μ M DSPE-PEG2k, 0.25 mM HPβ CD or the combination of the two chemicals. 
After 24 hours the cells were washed with PBS and then fixed with 4% methanol free-paraformaldehyde (Thermo 
Fisher) for 15 minutes at room temperature. The formaldehyde was washed off twice with PBS and then the cells 
were quenched with 100 mM glycine (Sigma) for 10 minutes. Next, the cells were permeabilized with 0.5% Triton 
X-100 (Sigma) for 10 minutes. Subsequently, cells were washed twice with PBS and then counter stained with 1x 
DAPI for 5 minutes at room temperature. The DAPI was washed off twice with PBS and then the coverslips were 
mounted onto Prolong Diamond Anti-fade reagent (Life Technologies). Mounted slides were cured overnight and 
then imaged on a Carl Zeiss LSM 780 confocal microscope at 100x magnification. Images were processed using 
ImageJ software.
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